BioNexus Gene Lab Corp (BGLC) stock
BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3090% below fair value
$0.77−0.05 (-6.56%)
Close on Nov 17, 2026Market cap $2.25MP/E –Yield –
BioNexus Gene Lab operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
BioNexus Gene Lab's operating income for the twelve months ending Jun 30, 2026 was -$2.56M. For fiscal 2025 it was -$2.97M. The highest annual figure on record is $1.27M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$2.97M | – |
| FY2024 | Dec 31, 2024 | -$1.57M | – |
| FY2023 | Dec 31, 2023 | -$2.59M | – |
| FY2022 | Dec 31, 2022 | -$291.18K | -127.6% |
| FY2021 | Dec 31, 2021 | $1.06M | -17.1% |
| FY2020 | Dec 31, 2020 | $1.27M | – |
| FY2019 | Dec 31, 2019 | -$275.71K | -560.3% |
| FY2018 | Dec 31, 2018 | $59.90K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$282.40K | – |
| Q1 FY2026 | Mar 31, 2026 | -$540.49K | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.03M | – |
| Q3 FY2025 | Sep 30, 2025 | -$702.51K | – |
| Q2 FY2025 | Jun 30, 2025 | -$611.29K | -335.9% |
| Q1 FY2025 | Mar 31, 2025 | -$618.42K | – |
| Q4 FY2024 | Dec 31, 2024 | -$416.22K | -261.5% |
| Q3 FY2024 | Sep 30, 2024 | -$1.34M | – |
| Q2 FY2024 | Jun 30, 2024 | $259.17K | – |
| Q1 FY2024 | Mar 31, 2024 | -$79.03K | – |
| Q4 FY2023 | Dec 31, 2023 | $257.75K | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.53M | – |
| Q2 FY2023 | Jun 30, 2023 | -$272.20K | – |
| Q1 FY2023 | Mar 31, 2023 | -$50.63K | -245.9% |
| Q4 FY2022 | Dec 31, 2022 | -$122.69K | -161.0% |
| Q3 FY2022 | Sep 30, 2022 | -$65.22K | -117.5% |
| Q2 FY2022 | Jun 30, 2022 | -$137.96K | -198.6% |
| Q1 FY2022 | Mar 31, 2022 | $34.69K | -89.9% |
| Q4 FY2021 | Dec 31, 2021 | $201.06K | – |
| Q3 FY2021 | Sep 30, 2021 | $372.64K | +57.0% |
| Q2 FY2021 | Jun 30, 2021 | $139.99K | – |
| Q1 FY2021 | Mar 31, 2021 | $342.10K | -68.1% |
| Q4 FY2020 | Dec 31, 2020 | -$3.04K | – |
| Q3 FY2020 | Sep 30, 2020 | $237.31K | – |
| Q2 FY2020 | Jun 30, 2020 | -$33.97K | – |
| Q1 FY2020 | Mar 31, 2020 | $1.07M | – |
| Q4 FY2019 | Dec 31, 2019 | -$96.15K | – |
| Q3 FY2019 | Sep 30, 2019 | -$50.14K | – |
| Q2 FY2019 | Jun 30, 2019 | -$69.22K | – |
| Q1 FY2019 | Mar 31, 2019 | -$60.20K | – |
| Q4 FY2018 | Dec 31, 2018 | -$63.35K | – |
| Q3 FY2018 | Sep 30, 2018 | -$55.14K | – |
| Q2 FY2018 | Jun 30, 2018 | -$39.47K | – |
See a number that looks wrong?